GUPEA >
Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Neuroscience and Physiology / Inst för neurovetenskap och fysiologi >
Doctoral Theses / Doktorsavhandlingar Institutionen för neurovetenskap och fysiologi >

Quantitative neuroproteomics for biomarker discovery in Alzheimer's disease


Please use this identifier to cite or link to this item: http://hdl.handle.net/2077/34813

Files in This Item:

File Description SizeFormat
gupea_2077_34813_1.pdfThesis frame1430KbAdobe PDF
View/Open
gupea_2077_34813_2.pdfAbstract727KbAdobe PDF
View/Open
Title: Quantitative neuroproteomics for biomarker discovery in Alzheimer's disease
Authors: Hölttä, Mikko
E-mail: mikko.holtta@gu.se
Issue Date: 17-Jan-2014
University: University of Gothenburg. Sahlgrenska Academy
Institution: Institute of Neuroscience and Physiology. Department of Psychiatry and Neurochemistry
Parts of work: I. Hölttä M, Zetterberg H, Mirgorodskaya E, Mattsson N, Blennow K, Gobom J. Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS. PLoS One. 2012;7(8):e42555. Epub 2012 Aug 6. PubMed
VIEW ARTICLE


II. Hölttä M, Minthon M, Hansson O, Holmén-Larsson J, Pike I, Ward M, Kuhn K, Zetterberg H, Blennow K, Gobom J. Multiplexed quantitative proteomics and peptidomics of cerebrospinal fluid identify potential biomarkers for Alzheimer’s disease. Submitted.

Hölttä M, Dean R, Siemers E, Mawuenyega K, Sigurdson W, May P, Paul S, Holtzman D, Portelius E, Zetterberg H, Bateman R, Blennow K, Gobom J. Effects of γ-secretase inhibition on endogenous peptides in human cerebrospinal fluid. Manuscript.
Date of Defence: 2014-02-07
Disputation: Fredagen den 7:e februari 2014, kl 13.00, Hörsal Hjärtats aula, Vita stråket 12, Sahlgrenska universitetssjukhuset
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: Alzheimer's disease
cerebrospinal fluid
biomarker discovery
proteomics
peptidomics
Abstract: Alzheimer’s disease (AD) is the most common form of dementia characterized by amyloid plaques and neurofibrillary tangles in the brain. Novel biomarkers for AD are needed that reflect disease progression and could identify subjects at risk of developing AD at an asymptomatic stage. The aim of this thesis was to develop methods that can be used to quantify endogenous peptides and proteins in cerebrospinal fluid (CSF) to identify potential biomarkers for AD. A workflow was developed for preparati... more
ISBN: 978-91-628-8895-4
URI: http://hdl.handle.net/2077/34813
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Doctoral Theses / Doktorsavhandlingar Institutionen för neurovetenskap och fysiologi

 

 

© Göteborgs universitet 2011